Real‐World Effectiveness and Safety of Damoctocog Alfa Pegol in Severe and Nonsevere Patients With Hemophilia A From the Prospective, Multinational, Ongoing HEM ‐ POWR Study
European Journal of Haematology · 2026
DOI: 10.1111/ejh.70026 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Haematology, 2026. Verfasst von Mark T Reding und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Bleeding and Clotting Disorders, University of Minnesota Medical Center, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Factor VIII, Hemophilia A. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bayer.
Abstract (Originalsprache)
Objectives
To assess the effectiveness and safety of damoctocog alfa pegol in patients with severe and nonsevere hemophilia A in the fifth interim analysis of the ongoing HEM‐POWR study.
Methods
HEM‐POWR (NCT03932201) is a multinational, Phase 4, prospective observational study. The key objectives were the annualized bleeding rate (ABR) and adverse events.
Results
At data cutoff (July 8, 2024), the safety analysis set and full analysis set (FAS) included 370 and 270 patients, respectively. In the modified FAS (patients with ≥ 90 days of bleed data), the mean (standard deviation; SD) ABR for total bleeds was 2.8 (5.9) 12 months prior to damoctocog alfa pegol initiation with the previous FVIII product and 2.1 (4.8) during the observation period. Bleed protection with damoctocog alfa pegol was maintained across disease severity, age group, BMI group, dosing regimen, and patient inhibitor history. One patient died due to spinal cord ischemia unrelated to the study drug. One patient developed a transient low‐titer inhibitor, which resolved without clinical consequence.
Conclusions
This updated analysis further demonstrated the effectiveness, acceptable safety profile, and tolerability of damoctocog alfa pegol for previously treated patients with severe and nonsevere hemophilia A from adolescence to older age in a real‐world setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Bleeding and Clotting Disorders, University of Minnesota Medical Center, Minneapolis, Minnesota, USA.
- Thrombosis and Haemostasis Unit, Hospital Universitario La Paz, Madrid, Spain.
- Department of Oncology, Center for Bleeding Disorders and Coagulation, Careggi University Hospital, Florence, Italy.
- Deming Department of Internal Medicine, Section of Hematology and Medical Oncology, Tulane School of Medicine, New Orleans, Louisiana, USA.
- Department of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan.
- Department of Hematology, University Medical Center Groningen, Groningen, the Netherlands.
Förderung
- Bayer
Zitieren
APA
Reding, M. T., Alvarez Román, M. T., Castaman, G., Janbain, M., Matsushita, T., Meijer, K., Schmidt, K., & Oldenburg, J. (2026). Real‐World Effectiveness and Safety of Damoctocog Alfa Pegol in Severe and Nonsevere Patients With Hemophilia A From the Prospective, Multinational, Ongoing HEM ‐ POWR Study. European Journal of Haematology. https://doi.org/10.1111/ejh.70026
Vancouver
Reding MT, Alvarez Román MT, Castaman G, Janbain M, Matsushita T, Meijer K, et al. Real‐World Effectiveness and Safety of Damoctocog Alfa Pegol in Severe and Nonsevere Patients With Hemophilia A From the Prospective, Multinational, Ongoing HEM ‐ POWR Study. European Journal of Haematology. 2026. doi:10.1111/ejh.70026
BibTeX
@article{Reding2026,
author = {Reding, Mark T and Alvarez Román, María Teresa and Castaman, Giancarlo and Janbain, Maissaa and Matsushita, Tadashi and Meijer, Karina and Schmidt, Kathrin and Oldenburg, Johannes},
title = {Real‐World Effectiveness and Safety of Damoctocog Alfa Pegol in Severe and Nonsevere Patients With Hemophilia A From the Prospective, Multinational, Ongoing HEM ‐ POWR Study},
journal = {European Journal of Haematology},
year = {2026},
doi = {10.1111/ejh.70026}
}
EUVIMED